MEDICLIN AG
ISIN: DE0006595101
WKN: 659510
31 July 2025 01:13PM

EQS-News: MEDICLIN reports positive interim results for the first half of 2025

MEDICLIN AG · ISIN: DE0006595101 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 2177630

EQS-News: MEDICLIN AG / Key word(s): Half Year Report/Half Year Results
MEDICLIN reports positive interim results for the first half of 2025

31.07.2025 / 13:13 CET/CEST
The issuer is solely responsible for the content of this announcement.


Offenburg, 31 July 2025
MEDICLIN reports positive interim results for the first half of 2025
                                                                             
  • Group operating result amounts to EUR 22.4 mill. (6M 2024: EUR 11,9 mill.)
  • Consolidated group sales amounts to EUR 383.8 mill. (6M 2024: EUR 368.0 mill.)
  • Overall capacity utilisation stable at 86.1%
 
Offenburg, 31 July 2025: In the first half of 2025, MEDICLIN Aktiengesellschaft (ticker: MED; WKN 659 510) generated consolidated group sales of EUR 383.8 mill. This represents an increase of EUR 15.8 mill. or 4.3% compared with the first half of 2024. The Group operating result improved by EUR 10.4 mill. to EUR 22.4 mill. compared to the same period last year (6M 2024: EUR 11.9 mill.). The Group's overall capacity utilisation remained stable at 86.1% (6M 2024: 85.7%).

“We succeeded in maintaining our earnings power at a stable level and in increasing efficiency in the individual segments. The solid overall capacity utilisation and the increase in the group operating result underscore our sustainable growth strategy,” said Tino Fritz, CFO of MEDICLIN, commenting on the development in the first half of 2025.

Developments in the segments

In the Post-Acute segment, sales increased by 10.2% to EUR 257.0 mill. (6M 2024: EUR 233.3 mill.). The segment operating result rose by EUR 5.8 mill. to EUR 23.3 mill. (6M 2024: EUR 17.5 mill.). The cost of materials ratio fell by one percentage point to 20.1% (6M 2024: 21.1%). At EUR 51.6 mill., the absolute cost of materials was 4.8% above the previous year's figure (6M 2024: EUR 49.3 mill.). Personnel expenses increased by EUR 12.7 mill. or 10.1% to EUR 138.3 mill. compared with the first half of the previous year, mainly due to the usual salary increases for existing staff. The personnel expense ratio remained constant at 53.8%.

Developments in the Acute segment are driven by the sale of the former MEDICLIN Herzzentrum Coswig. Segment sales declined by EUR 8.6 mill. or 7.2%.  The cost of materials fell by 10.6% to EUR 31.0 mill. (6M 2024: EUR 34.7 mill.). The cost of materials as a percentage of revenue declined slightly to 27.8% (6M 2024: 28.9%). Personnel expenses amounted to EUR 68.6 mill., down 7.3% on the previous year (6M 2024: EUR 74.0 mill.). The personnel expense ratio remained virtually unchanged at 61.4% (6M 2024: 61.5%). Operating result improved by EUR 2.8 mill. or 71.5% to EUR 1.1 mill. (6M 2025: EUR –3.9 mill.).

Sales in the Care segment rose to EUR 12.4 mill. in the first half of 2025 (6M 2024: EUR 11.7 mill.), while the segment operating result was slightly below the prior-year period at EUR –0.3 mill. (6M 2024: EUR –0.1 mill.).

In the Service segment, sales increased by EUR 2.0 mill. to EUR 50.3 mill. (6M 2024: EUR 48.2 mill.). At EUR 0.5 mill., the segment operating result was EUR 2.0 mill. higher than in the same period of the previous year (6M 2024: EUR –1.6 mill.).

Outlook and current events

For the current financial year, the Management Board continues to expect an increase in consolidated group sales of between 2.0% and 5.0% and consolidated operating profit of between EUR 53.0 mill. and EUR 64.0 mill.

The interim report as of 30 June 2025 is available in German and English at www.mediclin.de as of today.

For more information:

MEDICLIN Aktiengesellschaft
Okenstraße 27
77652 Offenburg
Germany

Investor Relations
Ender Gülcan
Phone +49 781/488-326
ender.guelcan@mediclin.de


www.mediclin.de


About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)
MEDICLIN includes 31 clinics, six care facilities and nine medical care centers. The group has around 8,200 beds/care places and employs around 9,900 people.
In a strong network, MEDICLIN offers the patients integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a company of the Asklepios Group

 


31.07.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MEDICLIN AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: ender.guelcan@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2177630

 
End of News EQS News Service

2177630  31.07.2025 CET/CEST

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2019 2020 2021 2022 2023 2024 2025e
Sales1 673,09 659,86 673,14 704,70 730,07 748,75 778,00
EBITDA1,2 93,58 77,50 85,22 90,92 98,73 103,77 115,00
EBITDA-Margin3 13,90 11,75 12,66 12,90 13,52 13,86 14,78
EBIT1,4 22,41 0,15 11,56 19,52 12,72 53,49 63,00
EBIT-Margin5 3,33 0,02 1,72 2,77 1,74 7,14 8,10
Net Profit (Loss)1 9,68 -0,04 1,49 9,72 -10,72 24,91 35,00
Net-Margin6 1,44 -0,01 0,22 1,38 -1,47 3,33 4,50
Cashflow1,7 69,59 118,69 81,97 34,64 78,00 50,57 74,00
Earnings per share8 0,20 -0,19 0,03 0,20 -0,23 0,52 0,74
Dividend per share8 0,05 0,00 0,00 0,00 0,00 0,04 0,04
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: KPMG

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Mediclin
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
659510 DE0006595101 AG 179,55 Mio € 06.12.2000 Kaufen 8FW9FWGV+63
* * *
PE 2026e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
5,82 17,70 0,33 17,10 0,73 2,23 0,24
Dividends
Dividend '2023
in €
Dividend '2024
in €
Dividend '2025e
in €
Div.-Yield '2025e
in %
0,00 0,04 0,04 1,06%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
28.06.2026 04.05.2026 30.07.2026 04.11.2025 27.03.2026
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+0,00%
3,78 €
ATH 15,02 €
+12,80% +22,77% +56,20% +52,42% -65,64%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2025          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2025 by Gereon Kruse #BGFL